Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1.-20. (cancelled)

21. (currently amended) A method for assessing the effect of a composition or treatment on human prostate cancer, comprising:

a) providing an immune deficient mouse comprising a human prostate cancer xenograft of locally advanced or metastatic prostate cancer tissue or a cell suspension thereof, wherein the xenograft is allowed to grow for a sufficient time to permit the detection of a tumor or ~~the detection~~ of metastatic prostate cancer cells, and wherein the xenograft simulates disease progression from androgen-dependence to androgen-independence;

b) subjecting the mouse to the composition or treatment; and,

c) determining the effect of the composition or treatment on the growth of the xenograft in said mouse.

22. (previously presented) The method of claim 21, wherein the determining step comprises comparing the growth of the xenograft in the mouse provided in step (a) and subjected to the composition or treatment in step (b) to the growth of the xenograft in at least one immune deficient mouse as set forth in step (a) that did not receive the composition or treatment.

23. (previously presented) The method of claim 21, wherein the xenograft is a subcutaneous xenograft.

24. (previously presented) The method of claim 21, wherein the xenograft is an intraprostatic xenograft.

25. (previously presented) The method of claim 21, wherein the xenograft is within a bone marrow cavity of the mouse.

26. (previously presented) The method of claim 21, wherein:

i) the efficacy of the composition or treatment of step (b) for treating human prostate cancer is not known; and,

ii) step (c) determines that the treatment or composition is efficacious in impairing the growth of the human prostate cancer xenograft in the mouse.

27.-34. (cancelled)

35. (previously presented) The method of claim 21, wherein the immune deficient mouse is a SCID mouse.